Logo image of ALDVI.PA

ADVICENNE (ALDVI.PA) Stock Fundamental Analysis

EPA:ALDVI - Euronext Paris - Matif - FR0013296746 - Common Stock - Currency: EUR

1.73  -0.05 (-2.81%)

Fundamental Rating

2

Taking everything into account, ALDVI scores 2 out of 10 in our fundamental rating. ALDVI was compared to 52 industry peers in the Pharmaceuticals industry. ALDVI may be in some trouble as it scores bad on both profitability and health. ALDVI shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALDVI had negative earnings in the past year.
ALDVI had a negative operating cash flow in the past year.
ALDVI had negative earnings in each of the past 5 years.
In the past 5 years ALDVI always reported negative operating cash flow.
ALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFALDVI.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M

1.2 Ratios

ALDVI's Return On Assets of -88.23% is on the low side compared to the rest of the industry. ALDVI is outperformed by 88.46% of its industry peers.
Industry RankSector Rank
ROA -88.23%
ROE N/A
ROIC N/A
ROA(3y)-67.64%
ROA(5y)-64.85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALDVI.PA Yearly ROA, ROE, ROICALDVI.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALDVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALDVI.PA Yearly Profit, Operating, Gross MarginsALDVI.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

More info and screens

0

2. Health

2.1 Basic Checks

ALDVI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALDVI has more shares outstanding
ALDVI has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALDVI has a worse debt to assets ratio.
ALDVI.PA Yearly Shares OutstandingALDVI.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALDVI.PA Yearly Total Debt VS Total AssetsALDVI.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

ALDVI has an Altman-Z score of -8.29. This is a bad value and indicates that ALDVI is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -8.29, ALDVI is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.29
ROIC/WACCN/A
WACC6.28%
ALDVI.PA Yearly LT Debt VS Equity VS FCFALDVI.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M 30M

2.3 Liquidity

ALDVI has a Current Ratio of 0.36. This is a bad value and indicates that ALDVI is not financially healthy enough and could expect problems in meeting its short term obligations.
ALDVI's Current ratio of 0.36 is on the low side compared to the rest of the industry. ALDVI is outperformed by 88.46% of its industry peers.
A Quick Ratio of 0.26 indicates that ALDVI may have some problems paying its short term obligations.
The Quick ratio of ALDVI (0.26) is worse than 88.46% of its industry peers.
Industry RankSector Rank
Current Ratio 0.36
Quick Ratio 0.26
ALDVI.PA Yearly Current Assets VS Current LiabilitesALDVI.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

8

3. Growth

3.1 Past

ALDVI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.91%, which is quite impressive.
Looking at the last year, ALDVI shows a very strong growth in Revenue. The Revenue has grown by 25.67%.
Measured over the past years, ALDVI shows a very strong growth in Revenue. The Revenue has been growing by 25.03% on average per year.
EPS 1Y (TTM)40.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.76%
Revenue 1Y (TTM)25.67%
Revenue growth 3Y12.58%
Revenue growth 5Y25.03%
Sales Q2Q%4.94%

3.2 Future

The Earnings Per Share is expected to grow by 20.61% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 31.54% on average over the next years. This is a very strong growth
EPS Next Y-3.51%
EPS Next 2Y17.73%
EPS Next 3Y20.61%
EPS Next 5YN/A
Revenue Next Year27.59%
Revenue Next 2Y24.57%
Revenue Next 3Y31.54%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALDVI.PA Yearly Revenue VS EstimatesALDVI.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
ALDVI.PA Yearly EPS VS EstimatesALDVI.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALDVI. In the last year negative earnings were reported.
Also next year ALDVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALDVI.PA Price Earnings VS Forward Price EarningsALDVI.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALDVI.PA Per share dataALDVI.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as ALDVI's earnings are expected to grow with 20.61% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.73%
EPS Next 3Y20.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALDVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADVICENNE

EPA:ALDVI (3/7/2025, 7:00:00 PM)

1.73

-0.05 (-2.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)09-18 2024-09-18
Earnings (Next)03-27 2025-03-27/amc
Inst Owners23%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.31M
Analysts84.44
Price Target4.08 (135.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.36
Fwd EYN/A
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0.24
BVpS-1.41
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -88.23%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-67.64%
ROA(5y)-64.85%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.81%
Cap/Sales 23.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.36
Quick Ratio 0.26
Altman-Z -8.29
F-Score5
WACC6.28%
ROIC/WACCN/A
Cap/Depr(3y)237.24%
Cap/Depr(5y)256.59%
Cap/Sales(3y)19.87%
Cap/Sales(5y)28.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-21.76%
EPS Next Y-3.51%
EPS Next 2Y17.73%
EPS Next 3Y20.61%
EPS Next 5YN/A
Revenue 1Y (TTM)25.67%
Revenue growth 3Y12.58%
Revenue growth 5Y25.03%
Sales Q2Q%4.94%
Revenue Next Year27.59%
Revenue Next 2Y24.57%
Revenue Next 3Y31.54%
Revenue Next 5YN/A
EBIT growth 1Y34.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year12.31%
EBIT Next 3Y16.21%
EBIT Next 5YN/A
FCF growth 1Y39.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.04%
OCF growth 3YN/A
OCF growth 5YN/A